TOI — Oncology Institute Income Statement
0.000.00%
Last trade - 00:00- $250.74m
- $294.21m
- $393.41m
- 40
- 31
- 94
- 55
Annual income statement for Oncology Institute, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 188 | 203 | 252 | 324 | 393 |
| Cost of Revenue | |||||
| Gross Profit | 36.9 | 40.8 | 52.1 | 59.6 | 54 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 196 | 244 | 334 | 401 | 454 |
| Operating Profit | -8.2 | -40.9 | -81.8 | -77 | -60.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -14.8 | -11.6 | -0.091 | -83.1 | -64.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -14.3 | -10.9 | 0.152 | -83.1 | -64.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -14.3 | -10.9 | 0.152 | -83.1 | -64.7 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -14.3 | -10.9 | 0.068 | -67.9 | -53 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.192 | -0.193 | 0.163 | -0.729 | -0.63 |
| Dividends per Share |